永泰生物-B 于2025年9月获海南ATL临床转化应用附条件批准

美股速递
Jun 03

永泰生物-B 宣布,其于2025年9月获得了在海南进行ATL临床转化应用的附条件批准。这一进展标志着公司在特定治疗领域的研发向前迈出了关键一步,为其相关技术或产品在特定区域的临床推进奠定了基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10